Cytomegalovirus antibody status at 17-18 weeks of gestation and pre-eclampsia: a case-control study of pregnant women in Norway.
In: BJOG: An International Journal of Obstetrics & Gynaecology, Jg. 119 (2012-10-01), Heft 11, S. 1316-1323
academicJournal
Zugriff:
Please cite this paper as: Strand K, Odland M, Iversen A, Nordbø S, Vik T, Austgulen R. Cytomegalovirus antibody status at 17-18 weeks of gestation and pre-eclampsia: a case-control study of pregnant women in Norway. BJOG 2012;119:1316-1323. Objective To assess the association between maternal cytomegalovirus (CMV) antibodies in mid-pregnancy and pre-eclampsia. Design Nested case-control study. Setting Pregnancies registered in the Norwegian Mother and Child Cohort Study (MoBa): a large population-based pregnancy cohort (1999-2006). Sample A cohort of 1500 women with pre-eclampsia and 1000 healthy pregnant women. Methods Plasma samples and pregnancy-related information were provided by the MoBa. Antibody status (CMV IgG and CMV IgM) and levels (CMV IgG) at 17-18 weeks of gestation were determined by enzyme-linked immunosorbent assay (ELISA). Main outcome measure A diagnosis of pre-eclampsia, as defined in the Medical Birth Registry of Norway. Results There was no evidence of an effect of CMV IgG seropositivity on the likelihood of developing pre-eclampsia, and CMV IgG antibody levels among women who were seropositive did not differ between groups. Adjusted for maternal age, parity and smoking, the odds ratio for pre-eclampsia in women seropositive for CMV IgG was 0.89 (95% CI 0.74-1.05; P = 0.17). The proportions of women who were seropositive for IgM did not differ between women with pre-eclampsia and women who were healthy ( P = 0.98). Among nulliparous women, the proportion of women who were seropositive for CMV IgG was slightly lower among women with pre-eclampsia (53.5%) than among healthy women (59.8%) ( P = 0.03). Subgroup analyses were performed for women with early or late onset pre-eclampsia, with preterm delivery and/or with neonates that were small for gestational age, but antibody status did not differ between pre-eclampsia subtypes and controls. Conclusions The presence of maternal antibodies to CMV was not associated with pre-eclampsia in our study. The results suggest that CMV infection is unlikely to be a major cause of pre-eclampsia. [ABSTRACT FROM AUTHOR]
Titel: |
Cytomegalovirus antibody status at 17-18 weeks of gestation and pre-eclampsia: a case-control study of pregnant women in Norway.
|
---|---|
Autor/in / Beteiligte Person: | Strand, KM ; Odland, ML ; Iversen, A-C ; Nordbø, SA ; Vik, T ; Austgulen, R |
Zeitschrift: | BJOG: An International Journal of Obstetrics & Gynaecology, Jg. 119 (2012-10-01), Heft 11, S. 1316-1323 |
Veröffentlichung: | 2012 |
Medientyp: | academicJournal |
ISSN: | 1470-0328 (print) |
DOI: | 10.1111/j.1471-0528.2012.03420.x |
Schlagwort: |
|
Sonstiges: |
|